

PRESCRIPTION INFORMATION AND ENROLLMENT FORM
Healthcare Provider must complete and fax this form to ProCare Rx: 855-818-3781

PATIENT INFORMATION

Patient Name: _____ DOB: _____
Address: _____ Address 2: _____
City: _____ State: _____ Zip Code: _____
Phone Number: _____ E-mail (optional): _____

PRESCRIBER INFORMATION

Provider Name: _____ NPI: _____
Address: _____ Address 2: _____
City: _____ State: _____ Zip Code: _____
Key Contact: _____ Email: _____
Phone Number: _____ Fax Number: _____

PRESCRIPTION INFORMATION

Rx: **Nerivio** Quantity: 1 Refills: 12 24 Other _____

Directions: Begin treatment within 60 minutes of migraine onset. Set a strong, yet comfortable intensity level for each 45-minute treatment.

- Diagnosis (Select ICD10):**
- G43.709** Chronic migraine without aura, not intractable, without status migrainosus
 - G43.009** Migraine without aura, not intractable, without status migrainosus
 - G43.109** Migraine with aura, not intractable, without status migrainosus
 - G43.719** Chronic migraine without aura, intractable, without status migrainosus
 - G43.711** Chronic migraine without aura, intractable, with status migrainosus
 - G43.909** Migraine, unspecified, not intractable, without status migrainosus
 - G43.** ___ ___ (Fill in 3 digits to complete diagnosis code)

Clinical Criteria

- Tried and failed abortive generic migraine medications (check all that apply)
- | | | |
|------------------------------------|-----------------------------------|------------------------------------|
| <input type="radio"/> Sumatriptan | <input type="radio"/> Rizatriptan | <input type="radio"/> Eletriptan |
| <input type="radio"/> Zolmitriptan | <input type="radio"/> Almotriptan | <input type="radio"/> Other: _____ |

Prescriber Signature: _____ Date: _____

METHODS OF PATIENT ENROLLMENT:

Attach, email or fax patient's insurance information if possible

Fax form to ProCare Rx: 855-818-3781 | Email form to ProCare Rx: neriviorx@procarerx.com

E-prescribe to ProMod Rx (Miramar, FL)

NCPDP: 5742627 NPI: 1396394805

Please provide this product summary along with the prescription form to your Healthcare Provider




Nerivio®


FDA Cleared, Non-pharmacologic Acute Treatment for Migraine Patients Age 12 and Over

Nerivio is an innovative remote electrical neuromodulation (REN) wearable device applied to the upper arm at the onset of migraine headaches or aura. Upon stimulation of peripheral nerves in the upper arm, Nerivio can abort or significantly relieve migraine attacks.

Clinical Trials: Acute Treatment of Migraine



Yarnitsky, et al 2019, Headache



Hershey et al, 2020, Headache

Safety in adults:

Nerivio is well tolerated. 96.4% of adult patients studied did not report any device-related side effects. The reported device-related side effects were mild, did not require treatment, and were temporal. There were no systemic side effects, no serious adverse events (SAEs), and no discontinuations due to adverse events.

Safety in adolescents:

One mild device-related adverse event (temporary feeling of pain in arm, resolved after the treatment without requiring intervention). No device-related serious adverse events. None of the participants withdrew from the study due to device-related adverse events.


Large Size Real-World Evidence Analysis: Acute Treatment of Migraine

12,368
users analyzed
(85.1% Female)

2,514
with evaluable treatments
(86.8% Female)

Total of 121,947 treatments
(10.4% with moderate or severe pain)

Efficacy: Consistent pain response at 2 hours



Note: *2,514 patients: patients who had at least 4 evaluable treatments for the pain response analysis, i.e.: for at least 4 treatments, a patient answered the pain level question at baseline (treatment initiation) and post 2 hours (from treatment initiation).

Safety: adverse events in 59 out of 12,368 users (0.48%)



Mild -
56 users
(0.45%)



Moderate -
3
(0.03%)



Severe -
none

AilaniJ, Rabany L, Tamir S, Ironi A, Starling A. (2022). Real-World Analysis of Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine. Front. Pain Research.

INDICATION FOR USE:

Nerivio® is indicated for acute treatment of migraine with or without aura in patients 12 years of age or older. Nerivio is a prescription use, self administered device for use in the home environment at the onset of migraine headache or aura.

IMPORTANT SAFETY INFORMATION:

Nerivio® should not be used by people with congestive heart failure, severe cardiac or cerebrovascular disease, or uncontrolled epilepsy. Nerivio® should not be used by anyone with active implantable medical devices (e.g., pacemaker, hearing aid implant). It should only be applied to the upper arm over dry, healthy skin with normal physical sensation and without any metallic implants or in proximity to cancerous lesions. Nerivio has not been evaluated in pregnancy or those under the age of 12. For full use instructions and safety information, please see the Nerivio® QuickStart Guide.

Scan for quick access to Nerivio site:

